Search

Your search keyword '"Hershman, D. L."' showing total 895 results
Start Over "Hershman, D. L."

Refine your results

more »

more »

more »

more »

more »

more »

more »
895 results on '"Hershman, D. L."'

8. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update

Author

Loprinzi, C, Lacchetti, C, Bleeker, J, Cavaletti, G, Chauhan, C, Hertz, D, Kelley, M, Lavino, A, Lustberg, M, Paice, J, Schneider, B, Lavoie Smith, E, Smith, M, Smith, T, Wagner-Johnston, N, Hershman, D, Loprinzi C. L., Lacchetti C., Bleeker J., Cavaletti G., Chauhan C., Hertz D. L., Kelley M. R., Lavino A., Lustberg M. B., Paice J. A., Schneider B. P., Lavoie Smith E. M., Smith M. L., Smith T. J., Wagner-Johnston N., Hershman D. L., Loprinzi, C, Lacchetti, C, Bleeker, J, Cavaletti, G, Chauhan, C, Hertz, D, Kelley, M, Lavino, A, Lustberg, M, Paice, J, Schneider, B, Lavoie Smith, E, Smith, M, Smith, T, Wagner-Johnston, N, Hershman, D, Loprinzi C. L., Lacchetti C., Bleeker J., Cavaletti G., Chauhan C., Hertz D. L., Kelley M. R., Lavino A., Lustberg M. B., Paice J. A., Schneider B. P., Lavoie Smith E. M., Smith M. L., Smith T. J., Wagner-Johnston N., and Hershman D. L.

Abstract

PURPOSE To update the ASCO guideline on the recommended prevention and treatment approaches in the management of chemotherapy-induced peripheral neuropathy (CIPN) in adult cancer survivors. METHODS An Expert Panel conducted targeted systematic literature reviews to identify new studies. RESULTS The search strategy identified 257 new references, which led to a full-text review of 87 manuscripts. A total of 3 systematic reviews, 2 with meta-analyses, and 28 primary trials for prevention of CIPN in addition to 14 primary trials related to treatment of established CIPN, are included in this update. RECOMMENDATIONS The identified data reconfirmed that no agents are recommended for the prevention of CIPN. The use of acetyl-L-carnitine for the prevention of CIPN in patients with cancer should be discouraged. Furthermore, clinicians should assess the appropriateness of dose delaying, dose reduction, substitutions, or stopping chemotherapy in patients who develop intolerable neuropathy and/or functional impairment. Duloxetine is the only agent that has appropriate evidence to support its use for patients with established painful CIPN. Nonetheless, the amount of benefit from duloxetine is limited.

Published
2020

15. Effect of Metformin vs Placebo on and Metabolic Factors in NCIC CTG MA.32

Author

Goodwin, P. J., primary, Parulekar, W. R., additional, Gelmon, K. A., additional, Shepherd, L. E., additional, Ligibel, J. A., additional, Hershman, D. L., additional, Rastogi, P., additional, Mayer, I. A., additional, Hobday, T. J., additional, Lemieux, J., additional, Thompson, A. M., additional, Pritchard, K. I., additional, Whelan, T. J., additional, Mukherjee, S. D., additional, Chalchal, H. I., additional, Oja, C. D., additional, Tonkin, K. S., additional, Bernstein, V., additional, Chen, B. E., additional, and Stambolic, V., additional

Published
2015
Full Text
View/download PDF

16. Effects of a green tea extract, Polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor-negative breast cancer

Author

Crew, K. D., primary, Ho, K. A., additional, Brown, P., additional, Greenlee, H., additional, Bevers, T. B., additional, Arun, B., additional, Sneige, N., additional, Hudis, C., additional, McArthur, H. L., additional, Chang, J., additional, Rimawi, M., additional, Cornelison, T. L., additional, Cardelli, J., additional, Santella, R. M., additional, Wang, A., additional, Lippman, S. M., additional, and Hershman, D. L., additional

Published
2014
Full Text
View/download PDF

17. Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.

Author

Awada, Ahmad, Dirix, L., Manso Sanchez, L, Xu, B, Luu, T, Diéras, Véronique, Hershman, D L, Agrapart, V, Ananthakrishnan, R, Staroslawska, E, Awada, Ahmad, Dirix, L., Manso Sanchez, L, Xu, B, Luu, T, Diéras, Véronique, Hershman, D L, Agrapart, V, Ananthakrishnan, R, and Staroslawska, E

Abstract

Neratinib (HKI-272) is a potent irreversible pan-ErbB tyrosine kinase inhibitor with clinical activity in patients with ErbB2/HER2-positive breast cancer., Journal Article, Research Support, Non-U.S. Gov't, SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2013

18. Racial Disparities in Cancer Survival Among Randomized Clinical Trials Patients of the Southwest Oncology Group

Author

Albain, K. S., Albain, K. S., Unger, J. M., Crowley, J. J., Coltman, C. A., Hershman, D. L., Albain, K. S., Albain, K. S., Unger, J. M., Crowley, J. J., Coltman, C. A., and Hershman, D. L.

Abstract

BACKGROUND: Racial disparities in cancer outcomes have been observed in several malignancies. However, it is unclear if survival differences persist after adjusting for clinical, demographic, and treatment variables. Our objective was to determine whether racial disparities in survival exist among patients enrolled in consecutive trials conducted by the Southwest Oncology Group (SWOG). METHODS: We identified 19 457 adult cancer patients (6676 with breast, 2699 with lung, 1244 with colon, 1429 with ovarian, and 1843 with prostate cancers; 1291 with lymphoma; 2067 with leukemia; and 2208 with multiple myeloma) who were treated on 35 SWOG randomized phase III clinical trials from October 1, 1974, through November 29, 2001. Patients were grouped according to studies of diseases with similar histology and stage. Cox regression was used to evaluate the association between race and overall survival within each disease site grouping, controlling for available prognostic factors plus education and income, which are surrogates for socioeconomic status. Median and ten-year overall survival estimates were derived by the Kaplan-Meier method. All statistical tests were two-sided. RESULTS: Of 19 457 patients registered, 2308 (11.9%, range = 3.9%-21.6%) were African American. After adjustment for prognostic factors, African American race was associated with increased mortality in patients with early-stage premenopausal breast cancer (hazard ratio [HR] for death = 1.41, 95% confidence interval [CI] = 1.10 to 1.82; P = .007), early-stage postmenopausal breast cancer (HR for death = 1.49, 95% CI = 1.28 to 1.73; P < .001), advanced-stage ovarian cancer (HR for death = 1.61, 95% CI = 1.18 to 2.18; P = .002), and advanced-stage prostate cancer (HR for death = 1.21, 95% CI = 1.08 to 1.37; P = .001). No statistically significant association between race and survival for lung cancer, colon cancer, lymphoma, leukemia, or myeloma was observed. Additional adjustments for socioeconomic status d

Published
2009

19. Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer

Author

Yao, S, primary, Sucheston, L E, additional, Zhao, H, additional, Barlow, W E, additional, Zirpoli, G, additional, Liu, S, additional, Moore, H C F, additional, Thomas Budd, G, additional, Hershman, D L, additional, Davis, W, additional, Ciupak, G L, additional, Stewart, J A, additional, Isaacs, C, additional, Hobday, T J, additional, Salim, M, additional, Hortobagyi, G N, additional, Gralow, J R, additional, Livingston, R B, additional, Albain, K S, additional, Hayes, D F, additional, and Ambrosone, C B, additional

Published
2013
Full Text
View/download PDF

20. Racial Disparities in Posttraumatic Stress After Diagnosis of Localized Breast Cancer: The BQUAL Study

Author

Vin-Raviv, N., primary, Hillyer, G. C., additional, Hershman, D. L., additional, Galea, S., additional, Leoce, N., additional, Bovbjerg, D. H., additional, Kushi, L. H., additional, Kroenke, C., additional, Lamerato, L., additional, Ambrosone, C. B., additional, Valdimorsdottir, H., additional, Jandorf, L., additional, Mandelblatt, J. S., additional, Tsai, W.-Y., additional, and Neugut, A. I., additional

Published
2013
Full Text
View/download PDF

21. Phase I–II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo

Author

Ramaswamy, B., primary, Fiskus, W., additional, Cohen, B., additional, Pellegrino, C., additional, Hershman, D. L., additional, Chuang, E., additional, Luu, Thehang, additional, Somlo, G., additional, Goetz, M., additional, Swaby, R., additional, Shapiro, C. L., additional, Stearns, V., additional, Christos, P., additional, Espinoza-Delgado, I., additional, Bhalla, K., additional, and Sparano, J. A., additional

Published
2011
Full Text
View/download PDF

22. A phase III randomized trial of metformin versus placebo on recurrence and survival in early-stage breast cancer (BC) (NCIC Clinical Trials Group MA.32).

Author

Parulekar, W., primary, Chen, B. E., additional, Elliott, C., additional, Shepherd, L. E., additional, Gelmon, K. A., additional, Pritchard, K. I., additional, Whelan, T. J., additional, Ligibel, J. A., additional, Hershman, D. L., additional, Mayer, I. A., additional, Hobday, T. J., additional, Rastogi, P., additional, Lemieux, J., additional, Ganz, P. A., additional, Stambolic, V., additional, and Goodwin, P. J., additional

Published
2011
Full Text
View/download PDF

25. Bosutinib and exemestane (EXE) versus EXE alone in postmenopausal (postm) women with hormone receptor–positive (HR+) HER2-negative (HER2–) advanced breast cancer (ABC).

Author

Moy, B., primary, Lebrun, F., additional, Bellet, M., additional, Chow, L., additional, Lang, I., additional, Xu, B., additional, Badwe, R. A., additional, Hershman, D. L., additional, Leip, E., additional, Bardy-Bouxin, N., additional, Duvillie, L., additional, and Neven, P., additional

Published
2011
Full Text
View/download PDF

27. Randomized, double-blind, placebo-controlled phase II trial of low-dose metronomic cyclophosphamide alone or in combination with veliparib (ABT-888) in chemotherapy-resistant ER and/or PR-positive, HER2/neu-negative metastatic breast cancer: New York Cancer Consortium trial P8853.

Author

Andreopoulou, E., primary, Chen, A. P., additional, Zujewski, J., additional, Kim, M., additional, Hershman, D. L., additional, Kalinsky, K., additional, Cigler, T., additional, Vahdat, L. T., additional, Raptis, G., additional, Ramaswamy, B., additional, Novik, Y., additional, Muggia, F., additional, and Sparano, J. A., additional

Published
2011
Full Text
View/download PDF

48. Patient Experience of Interpersonal Processes of Care and Subsequent Utilization of Hormone Therapy for Non-Metastatic Breast Cancer.

Author

Poon, B. Y., Kroenke, C. H., Hillyer, G. C., Lamerato, L. E., Stewart, A. L., Neugut, A. I., Hershman, D. L., and Kushi, L. H.

Abstract

Purpose: We examined the association between patient experience of care and utilization of hormone therapy (HT) in the treatment of non-metastatic hormone-receptor positive (HR+) breast cancer. Methods: Patients newly diagnosed with non-metastatic breast cancer were recruited from 2006 to 2010 for a longitudinal multisite cohort study in New York, NY, Detroit, MI, and Northern California. Of 1,145 patients surveyed, 797 had HR+ tumors eligible for HT and all necessary data. We assessed patient experience 4 to 8 weeks after recruitment using 6 subscales of the Interpersonal Processes of Care (IPC) survey: compassion, discrimination, and hurriedness in communication, as well as concern elicitation, result explanation, and patient-centered decision-making. Subscales ranged from 1 to 5 where higher values indicated better experiences. HT for 5 years is standard care for HR+ breast cancer so utilization was defined as time from diagnosis to HT initiation and time from HT initiation to early discontinuation before 5 years as calculated from follow-up survey responses. We evaluated the relationship between patient experience and utilization using Cox proportional hazard models, controlling for education, income, insurance, marital status, social support, site of care, age at diagnosis, stage, grade, tumor size, Charlson comorbidity index, and chemotherapy. Results: Median age at diagnosis was 59 years (interquartile range 51-66) with the majority diagnosed at clinical stage 1 (54%) and with low or moderate grade disease (78%). Less hurried communication was associated with increased probability of HT initiation (Hazards Ratio (HR) 1.15; 95% Confidence Interval (CI) 1.03, 1.30; p = 0.018). Conversely, more patient-centered decision-making was associated with increased probability of early discontinuation (HR 1.29; CI, 1.03, 1.63; p = 0.028). All other associations were null. Conclusion: While unhurried communication was associated with initiation of hormone therapy, patient-centered decision-making was associated with early discontinuation. Different aspects of patient experience may have vastly different relationships with patient utilization of health services. Actionable assessments of patient experience may require measurement along multiple dimensions. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

49. ANNOTATED BIBLIOGRAPHY.

Author

Robson, M. E., Carey, L. A., Melisko, M. E., Denlinger, C. S., Goldstein, L. J., Hershman, D. L., Recht, A., Glück, S., Nagtegaal, I. D., Allred, D. C., Ma, C. X., Ellis, M. J., Swaby, R. F., Brufsky, A. M., Elledge, R. M., Hillner, B. E., and Loprinzi, C. L.

Subjects
DRUG therapy, BRCA genes, BREAST cancer, HORMONE therapy, PROTO-oncogenes
Abstract

The article presents abstracts on medical topics which include acute chemotherapy-related toxicity in BRCA1 and BRCA2 mutation carriers treated for breast cancer in Great Britain, neoadjuvant endocrine therapy for locally advanced breast cancer, and human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer.

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results